NanoVibronix, Inc. (NAOV) Financial Ratios
14 years of historical data (2011–2024) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.82
↓-97% vs avg
5yr avg: 27.92
30Y Low5.6·High161.4
ROE
↑
-160.6%
↓+14% vs avg
5yr avg: -187.4%
30Y Low-328%·High-103%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NAOV Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
NanoVibronix, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $512711 | $18M | $22M | $79M | $288M | $87M | $218M | $257M | $256M | $300M | $189M |
| Enterprise Value | $-123289 | $17M | $19M | $76M | $280M | $79M | $216M | $256M | $251M | $300M | $187M |
| P/E Ratio → | -0.14 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.20 | 6.85 | 9.70 | 104.66 | 169.83 | 138.93 | 410.46 | 807.73 | 1069.23 | 1310.74 | 1286.09 |
| P/B Ratio | 0.82 | 27.93 | 5.55 | 24.34 | 45.60 | 36.15 | 161.38 | 554.77 | 70.32 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NAOV EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.60 | 8.26 | 101.16 | 165.29 | 127.52 | 407.94 | 804.92 | 1050.99 | 1310.28 | 1275.12 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
NAOV Profitability
Margins and return-on-capital ratios measuring operating efficiency
NanoVibronix, Inc. earns an operating margin of -140.0%. Operating margins have expanded from -666.5% to -140.0% over the past 3 years, signaling improving operational efficiency. A negative ROE of -160.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.0% | 59.0% | 67.3% | 22.2% | 45.4% | 34.3% | 53.0% | 50.3% | 63.2% | 61.6% | 66.7% |
| Operating Margin | -140.0% | -140.0% | -150.5% | -666.5% | -335.3% | -757.5% | -971.9% | -1353.1% | -1293.3% | -1011.4% | -968.7% |
| Net Profit Margin | -144.8% | -144.8% | -162.5% | -724.5% | -842.6% | -694.4% | -1093.2% | -1306.3% | -2077.4% | -1236.2% | -1961.9% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -160.6% | -160.6% | -102.8% | -114.1% | -328.1% | -231.2% | -639.9% | -202.8% | -874.9% | — | — |
| ROA | -71.9% | -71.9% | -59.1% | -75.1% | -169.5% | -84.3% | -320.5% | -128.9% | -185.3% | -228.6% | -213.2% |
| ROIC | -766.5% | -766.5% | -393.1% | -625.5% | — | — | -38632.5% | — | — | — | — |
| ROCE | -139.7% | -139.7% | -88.3% | -97.5% | -94.4% | -135.7% | -401.3% | -171.8% | -154.7% | -286.8% | -84.5% |
NAOV Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $752000 exceeds total debt of $116000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.19 | 0.19 | 0.00 | 0.03 | 0.01 | 0.01 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.01 | -0.82 | -0.81 | -1.22 | -2.97 | -0.99 | -1.94 | -1.20 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -26.53 | -26.53 | -13.97 | -14.44 | — | -32.10 | -83.08 | -195.59 | -2.50 | -154.40 | -21.91 |
Net cash position: cash ($752000) exceeds total debt ($116000)
NAOV Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.22x means NanoVibronix, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 0.42x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 2.42x to 1.22x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.22 | 1.22 | 2.64 | 2.42 | 4.38 | 2.75 | 4.49 | 1.92 | 5.67 | 0.39 | 5.98 |
| Quick Ratio | 0.42 | 0.42 | 1.53 | 1.48 | 4.29 | 2.70 | 4.20 | 1.69 | 5.57 | 0.27 | 5.74 |
| Cash Ratio | 0.28 | 0.28 | 1.34 | 1.17 | 4.07 | 2.46 | 3.27 | 1.40 | 5.47 | 0.19 | 5.43 |
| Asset Turnover | — | 0.70 | 0.34 | 0.13 | 0.20 | 0.08 | 0.26 | 0.20 | 0.05 | 0.46 | 0.07 |
| Inventory Turnover | 0.48 | 0.48 | 0.27 | 0.27 | 5.29 | 2.82 | 2.06 | 1.10 | 1.16 | 1.31 | 0.69 |
| Days Sales Outstanding | — | 38.24 | 67.95 | 52.91 | 43.07 | 54.49 | 89.53 | 165.28 | 53.45 | 22.31 | 101.80 |
NAOV Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
NanoVibronix, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% |
| Shares Outstanding | — | $269848 | $175010 | $141967 | $125814 | $51490 | $34696 | $32242 | $24820 | $22892 | $17682 |
Peer Comparison
Compare NAOV with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NAOVYou | $512711 | -0.1 | — | — | 59.0% | -140.0% | -160.6% | -766.5% | — |
 ARAY | $35M | -18.9 | 11.0 | — | 32.1% | 1.7% | -2.5% | 3.0% | 12.6 |
 LNTH | $6B | 26.7 | 14.6 | 16.7 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 STIM | $128M | -3.1 | — | — | 48.5% | -21.1% | -134.4% | -26.6% | — |
 NSPR | $54M | -1.5 | — | — | 29.5% | -547.0% | -106.9% | -108.3% | — |
 GKOS | $8B | -40.9 | — | — | 77.5% | -17.1% | -26.4% | -9.2% | — |
 XTLB | $293767 | -0.3 | — | — | 0.7% | -481.6% | -26.8% | -54.1% | — |
 ANGO | $469M | -13.6 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
 MMSI | $4B | 29.3 | 13.1 | 17.2 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 BSX | $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See NAOV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NAOV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NAOV vs ARAY
Side-by-side business, growth, and profitability comparison vs Accuray Incorporated.
Start ComparisonNAOV — Frequently Asked Questions
Quick answers to the most common questions about buying NAOV stock.
What is NanoVibronix, Inc.'s P/E ratio?
NanoVibronix, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is NanoVibronix, Inc.'s ROE?
NanoVibronix, Inc.'s return on equity (ROE) is -160.6%. The historical average is -189.9%.
Is NAOV stock overvalued?
Based on historical data, NanoVibronix, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are NanoVibronix, Inc.'s profit margins?
NanoVibronix, Inc. has 59.0% gross margin and -140.0% operating margin.